ACADIA Pharmaceuticals Inc. (ACAD) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à San Diego, CA, United States. Le PDG actuel est Catherine E. Owen Adams.
ACAD a date d'introduction en bourse 2004-05-27, 653 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.75B.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, specializing in the development and commercialization of small molecule drugs for central nervous system disorders. The company's flagship product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes multiple late-stage candidates such as pimavanserin for Alzheimer's disease psychosis and schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain management, and ACP-319 for cognitive impairment in schizophrenia and Alzheimer's disease. Founded in 1993, ACADIA remains focused on addressing significant unmet medical needs in neuropsychiatric and neurological conditions.
